Skip to main content

Table 2 Criteria for withdrawal, reduction, and discontinuation of lenvatinib

From: Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report

Side Effects

Severity

Procedures

Hypertension

Systolic pressure ≥ 140 mmHg and diastolic pressure ≥ 90 mmHg

Continue using lenvatinib in combination with antihypertensive agents

Systolic pressure ≥ 160 mmHg and diastolic pressure ≥ 100 mmHg despite antihypertensive treatment

Withdraw until systolic pressure ≤ 150 mmHg or diastolic pressure ≤ 95 mmHg is achieved, followed by use of antihypertensive agents and resumption of lenvatinib treatment with a 1-stage reduction in dosage

Side effects (grade 4)

Discontinuation of lenvatinib

Other side effects

Side effects (grade 2 or 3)

Withdraw lenvatinib until baseline status is regained or the condition is ameliorated to grade ≤ 1. If resumed, then lenvatinib should be administered with a 1-stage reduction in dosage

Side effects (grade 4)

Discontinuation of lenvatinib

  1. The side effect grade is based on the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0). Grade 1: mild, with no symptoms or mild symptoms. Only clinical examination or laboratory testing is performed. Treatment is not required. Grade 2: moderate. Minimum/local/non-invasive treatments are required. Age-appropriate limitations of the activities of daily living, with the exception of personal commitments, are required as well. Grade 3: severe or clinically serious, no immediate threat to life, cannot be active/inoperable. Hospitalization or prolonged length of hospital stay is required. Limitations of the activities of daily living including personal commitments are required as well. Grade 4: life-threatening. Emergency treatment is required